Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck May Need New Arcoxia Trial Design Prior To FDA Approval

Executive Summary

Merck may need to conduct additional Arcoxia clinical trials to gain FDA approval after the agency and its COX-2 inhibitor advisory committee cited flaws in the existing program

You may also be interested in...



Merck Arcoxia MEDAL Results Will Likely Not Meet FDA Gold Standard

Despite the release of positive results from a long-term cardiovascular safety trial of its Vioxx follow-on Arcoxia, Merck will likely need to conduct additional studies before receiving FDA approval of the COX-2 inhibitor

Merck Arcoxia MEDAL Results Will Likely Not Meet FDA Gold Standard

Despite the release of positive results from a long-term cardiovascular safety trial of its Vioxx follow-on Arcoxia, Merck will likely need to conduct additional studies before receiving FDA approval of the COX-2 inhibitor

Mobic May Gain Momentum After Bextra Withdrawal

Boehringer Ingelheim's non-steroidal anti-inflammatory drug Mobic may be poised to emerge as a blockbuster product following the market withdrawal of Pfizer's COX-2 inhibitor Bextra

Related Content

Topics

UsernamePublicRestriction

Register

PS045477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel